



SYLVANT® (siltuximab) is a prescription medicine used to treat people with Multicentric Castleman's Disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT® is safe and effective in children.



## Multicentric Castleman's Disease

# How SYLVANT® May Help

- **INFORMATION ABOUT MULTICENTRIC CASTLEMAN'S DISEASE**
- **INFORMATION ON SYLVANT® THERAPY**
- **MORE RESOURCES**



## IMPORTANT SAFETY INFORMATION

### Who should not receive SYLVANT®?

Do not receive SYLVANT® if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT®.

**Please see the Important Safety Information on page 7.  
Please see Important Product Information in back pocket.**

# Causes and Symptoms of Multicentric Castleman's Disease

If you or a loved one has been diagnosed with Multicentric Castleman's Disease, you may have a lot of questions. This brochure is designed to help provide you with information you may need about Multicentric Castleman's Disease and a treatment option.

## What is Multicentric Castleman's Disease?

Multicentric Castleman's Disease (MCD) is a rare illness that affects the lymph nodes and related tissues.

The lymph system is a major part of the body's immune system that helps fight off infection.

With MCD, too many cells grow in the lymph nodes. This causes the lymph nodes to become enlarged. That makes it a lymphoproliferative disorder. A number of lymphoproliferative disorders exist, including lymphoma, which is cancer of the lymph system. Though MCD is not a cancer, having MCD may make some people more likely than others to develop lymphoma.

## What causes Multicentric Castleman's Disease?

Though the cause of MCD is not fully understood, it is believed that a protein in the body called interleukin-6 (IL-6) has a role in the disease.

When produced in normal amounts, IL-6 helps regulate the activity of the immune system. Often, high levels of IL-6 are seen in patients with MCD. As a result, white blood cells called lymphocytes multiply too rapidly. This causes the lymph nodes to become enlarged, and other symptoms may occur.

## What are some of the symptoms of Multicentric Castleman's Disease?

MCD can cause a number of symptoms, which may include:

- Enlarged lymph nodes (often in the neck, underarm, and groin)
- Enlarged liver, spleen, or other organs
- Fever
- Weakness and fatigue
- Night sweats (that soak the sheets)

These are not all of the possible symptoms of MCD. Symptoms of MCD usually come on gradually. For some patients, symptoms may begin after a viral infection.

# What You Should Know About SYLVANT® (siltuximab)

SYLVANT® is a prescription medicine for the treatment of patients with Multicentric Castleman's Disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. SYLVANT® was not studied in patients with MCD who are HIV positive or HHV-8 positive, because SYLVANT® did not bind to virally produced IL-6 in a nonclinical study.

If you have been diagnosed with MCD, your doctor may prescribe SYLVANT® for your illness. Here is some important information about SYLVANT®.

## How does SYLVANT® work?

SYLVANT® works by blocking the action of a substance produced in the lymph nodes called interleukin-6 (IL-6). SYLVANT® is a monoclonal antibody that prevents IL-6 from binding to IL-6 receptors.

## What are the possible side effects of SYLVANT®?

SYLVANT® may cause serious side effects, including:

**Infections.** SYLVANT® may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT®.

**Infusion and allergic reactions.** If you have an infusion or allergic reaction while receiving SYLVANT®, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction, your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT®: trouble breathing, chest tightness, wheezing, dizziness or lightheadedness, swelling of the lips, or skin rash.

**The most common side effects of SYLVANT® include:** rash, itching, upper respiratory tract infection, weight gain, and increased blood level of uric acid.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.


These are not all the possible side effects of SYLVANT®.

Report any signs of new or worsening medical conditions to your healthcare provider.

Call your doctor for medical advice about side effects.

Please see the additional Important Safety Information on page 7.

Please see Important Product Information in back pocket.



# Information on SYLVANT® (siltuximab) Therapy

## IMPORTANT SAFETY INFORMATION

Do not receive SYLVANT® if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT®.

**Before you receive SYLVANT®, tell your healthcare provider about all of your medical conditions, including if you:**

Have an infection. You should not receive SYLVANT® if you have a severe infection.

Have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT®.

Have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.

Are pregnant or plan to become pregnant. It is not known if SYLVANT® will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT®. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT® and for 3 months after stopping treatment. Are breastfeeding or plan to breastfeed. It is not known if SYLVANT® passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT® or breastfeed. You should not do both.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

**Please see additional Important Safety Information on next page.**

## How will I receive SYLVANT®?

You will receive SYLVANT® in a hospital or a clinic every 3 weeks. A doctor or nurse will give you the medicine through an intravenous (IV) infusion. It takes about an hour to get the SYLVANT® infusion, and you will be monitored for any possible side effects.

## How long will I stay on SYLVANT®?

Even if you are not experiencing symptoms, it is important to continue to receive treatment with SYLVANT® for as long as your doctor recommends.

If you have started therapy on SYLVANT® and are interested in receiving infusion appointment reminders, go to [www.sylvantone.com](http://www.sylvantone.com).

## How will I know if SYLVANT® is working for me?

You may have symptom relief, and your doctor will order tests to assess how you are doing on treatment. But it is also important for you to tell your doctor how you are feeling during each visit. To learn more about Multicentric Castleman's Disease (MCD) and SYLVANT®, or to access a tool to help you track your symptoms, visit [www.sylvantone.com](http://www.sylvantone.com).

# Creating a Strong Support System

## Where can I find support for living with Multicentric Castleman's Disease?

It may feel scary and confusing to find out that you have a serious illness such as Multicentric Castleman's Disease (MCD). You may have a lot of questions and concerns. Talking openly and honestly with your doctor, and taking an active role in your treatment, may help you feel more informed about and in control of your illness.

It can also help to talk to your family and friends about your illness and treatment, and to share your fears and concerns. Remember, you are not alone with your illness; let people know what they can do to help and support you. You may also find it comforting to speak with a counselor or spiritual advisor.

## IMPORTANT SAFETY INFORMATION

**The most common side effects of SYLVANT® include:** rash, itching, upper respiratory tract infection, weight gain, and increased blood level of uric acid. Call your doctor for medical advice about side effects.

**Please see the additional Important Safety Information on page 7.**

**Please see Important Product Information in back pocket.**

## How to explain your MCD to others

Let family and friends know that MCD is a rare disease. It is not a cancer, but it is a long-term illness that can be difficult to live with.

The symptoms of MCD are not always obvious. However, your family and friends should know that some of the symptoms you may experience—such as fatigue, weakness, and fevers—are very real and can impact your daily life.

It may help if your friends and family understand that, though treatment may help your symptoms, there is no cure for MCD. Even if you are not experiencing symptoms, it is important to continue to receive treatment with SYLVANT® for as long as your doctor recommends.



## Where can I get more information about Multicentric Castleman's Disease?

There are several organizations that have been formed to provide education, advocacy, research, and services for people with Multicentric Castleman's Disease (MCD)—the **Castleman Disease Collaborative Network**, **Castleman's Awareness and Research Effort**, and the **RareConnect Castleman Disease Community**. Through these organizations, you can connect with a community of patients, caregivers, and advocates who are all affected by the disease.

### Castleman Disease Collaborative Network

The Castleman Disease Collaborative Network's (CDCN) mission is to accelerate CD research, treatment, and patient care through global collaboration, strategic investments in research, and supportive resources for patients and their loved ones. For more information, please visit [www.cdcn.org](http://www.cdcn.org).

### Castleman's Awareness and Research Effort

Castleman's Awareness and Research Effort (CARE) supports and advocates for the ongoing effort to cure Castleman's Disease through raising awareness for the disease and funds to go towards research at top medical facilities and organizations. CARE is also the legal entity that supports the Castleman Disease Collaborative Network (CDCN). For more information, please visit [www.care4castlemans.org](http://www.care4castlemans.org).

### RareConnect Castleman Disease Community

RareConnect is a joint project of the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Diseases (NORD), with resources and online communities to help patients with rare diseases interact with and learn from their peers and medical experts. RareConnect Castleman Disease Community is a joint project between the CDCN and CARE, which offers details on these advocacy groups, information about living with Castleman's Disease, and a live forum. Members of the community can also contribute personal stories and submit questions. For more information, please visit [www.rareconnect.org/en/community/castleman-disease](http://www.rareconnect.org/en/community/castleman-disease).

## Additional resources

You may find more information and support about living with a rare disease at the following websites:

**American Cancer Society**  
[www.cancer.org/cancer/castlemandisease](http://www.cancer.org/cancer/castlemandisease)

**EURORDIS**  
[www.eurordis.org](http://www.eurordis.org)

**Genetic Alliance**  
[www.geneticalliance.org](http://www.geneticalliance.org)

**Global Genes Project**  
[www.globalgenes.org](http://www.globalgenes.org)

**NORD**  
[www.rarediseases.org](http://www.rarediseases.org)

## What is SYLVANT® (siltuximab)?

SYLVANT® (siltuximab) is a prescription medicine used to treat people with Multicentric Castleman's Disease (MCD) who do not have human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV-8) infection. It is not known if SYLVANT® is safe and effective in children.

## Who should not receive SYLVANT®?

Do not receive SYLVANT® if you have had a severe allergic reaction to siltuximab or any of the ingredients in SYLVANT®.

## What should I tell my healthcare provider before receiving SYLVANT®?

**Before you receive SYLVANT®, tell your healthcare provider about all of your medical conditions, including if you:**

Have an infection. You should not receive SYLVANT® if you have a severe infection.

Have had a recent vaccination or are scheduled to receive any vaccinations. You should not receive a live vaccine during your treatment with SYLVANT®.

Have or have had any stomach or bowel (intestine) problems, such as diverticulitis or ulcers. Tell your healthcare provider if you have pain in your stomach area.

Are pregnant or plan to become pregnant. It is not known if SYLVANT® will harm your unborn baby. You should not become pregnant while receiving treatment with SYLVANT®. Females who are able to become pregnant should use effective birth control during treatment with SYLVANT® and for 3 months after stopping treatment.

Are breastfeeding or plan to breastfeed. It is not known if SYLVANT® passes into your breast milk. You and your healthcare provider should decide if you will take SYLVANT® or breastfeed. You should not do both.

**Tell your healthcare provider about all the medicines you take**, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

## What are the possible side effects of SYLVANT®?

**SYLVANT® may cause serious side effects, including:**

**Infections.** SYLVANT® may lower your ability to fight infections. Tell your healthcare provider right away if you have any signs or symptoms of an infection during treatment with SYLVANT®.

**Infusion and allergic reactions.** If you have an infusion or allergic reaction while receiving SYLVANT®, your healthcare provider will stop your infusion and treat your reaction. If you have a severe infusion or allergic reaction your healthcare provider may stop your treatment completely. Tell your healthcare provider or get medical help right away if you have any of these symptoms during or after your infusion of SYLVANT®: trouble breathing, chest tightness, wheezing, dizziness or light-headedness, swelling of the lips, or skin rash.

**The most common side effects of SYLVANT® include:** rash, itching, upper respiratory tract infection, weight gain, and increased blood level of uric acid.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of SYLVANT®.

Call your doctor for medical advice about side effects.

## General information about the safe and effective use of SYLVANT®

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your healthcare provider or pharmacist for information about SYLVANT® that is written for health professionals.

Report any signs of new or worsening medical conditions to your healthcare provider.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088 (1-800-332-1088).

**Please see Important Product Information in back pocket.**

# SylvantOne™ Support helps simplify access to SYLVANT® (siltuximab)

## sylvantone™ SUPPORT

SylvantOne™ Support is a comprehensive, personalized support program designed to help simplify access to SYLVANT®. Your healthcare provider can help you enroll in this program before you start taking SYLVANT®. Ask your doctor about enrolling at your next appointment.

For more information about support services, please call SylvantOne™ Support or visit [SylvantOne.com](http://SylvantOne.com).

Please see the Important Safety Information on page 7.

Please see Important Product Information in back pocket.

### SylvantOne™ Support provides:

- Simplified explanation of insurance benefits and potential medication out-of-pocket expenses
- Information on the SylvantOne™ Patient Rebate Program, designed to assist you with medication out-of-pocket costs if you have commercial insurance
- Assistance with other cost support options, such as a patient assistance program if you are uninsured and eligible
- Access to educational materials and information related to SYLVANT®
- Access to personalized appointment reminders, which can help you remember your next scheduled appointment

sylvantone™  
SUPPORT

1-855-299-8844  
Monday–Friday, 8:00 AM–8:00 PM ET

### Bibliography

American Cancer Society. Castleman Disease. What is Castleman disease? <http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-what-is-castleman-disease>. Accessed July 20, 2015.

Castleman Disease Collaborative Network. Our Mission. <http://www.cdcn.org/about-us/our-mission>. Accessed July 21, 2015.

Castleman Disease Collaborative Network. Castleman's Awareness & Research Effort. <http://www.cdcn.org/about-us/partnership-with-care>. Accessed July 21, 2015.

Mayo Clinic. Castleman Disease. <http://www.mayoclinic.org/diseases-conditions/castleman-disease/basics/definition/con-20031703>. Accessed July 20, 2015.

RareConnect Castleman Disease (CD) Community. <https://www.rareconnect.org/en/community/castleman-disease>. Accessed July 21, 2015.

SYLVANT® [package insert]. Horsham, PA: Janssen Biotech, Inc.

SYLVANT® Important Safety Information. <http://www.sylvant.com/isi>. Accessed July 21, 2015.

SylvantOne™ Support Services. <http://www.sylvant.com/for-patients/sylvantone-support-services>. Accessed July 21, 2015.

van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. *Clin Adv Hematol Oncol*. 2010;8(7):486–498.

For additional information, visit [www.sylvant.com](http://www.sylvant.com).

© Janssen Biotech, Inc. 2015. All rights reserved.  
10/15 Printed in USA 035045-150601

